Literature DB >> 19415164

Visceral adiposity and leptin are independently associated with C-reactive protein in Korean type 2 diabetic patients.

Jong Suk Park1, Min Ho Cho, Ji Sun Nam, Chul Woo Ahn, Bong Soo Cha, Eun Jig Lee, Sung Kil Lim, Kyung Rae Kim, Hyun Chul Lee.   

Abstract

The inflammatory marker, C-reactive protein (CRP) is associated with long-term cardiovascular events. The aim of the study was to investigate the factors contributing to serum CRP, assess the relationship between CRP level and the parameters of visceral obesity, and examine the association between leptin and CRP level in type 2 diabetic patients. 150 patients with type 2 diabetes were enrolled. These patients were recently diagnosed (< or =3 years) with type 2 diabetes and were drug naive or taking sulfonylureas only. BMI, WC, and serum concentration of CRP, glycosylated hemoglobin (HbA1c), glucose, lipids, plasminogen activator-1 (PAI-1) and leptin were measured. Insulin resistance was estimated by the insulin resistance index of homeostasis model assessment (HOMA-IR). We measured the carotid intima-media thickness (IMT). Fat mass assessed by dual-energy X-ray absorptionmetry and abdominal fat distribution was determined by CT scan. Serum concentration of CRP was significantly correlated with BMI (gamma = 0.257, P < 0.01), WC (gamma = 0.293, P < 0.01), fat mass (gamma = 0.213, P < 0.01), total adipose tissue (gamma = 0.263, P < 0.01), visceral adipose tissue (gamma = 0.296, P < 0.01), insulin (gamma = 0.189, P = 0.047), PAI-1 (gamma = 0.206, P < 0.01), leptin (gamma = 0.322, P < 0.01), mean IMT (gamma = 0.132, P = 0.042), and HOMA-IR (gamma = 0.172, P = 0.045). After adjustment for age and gender, multiple regression analysis showed that serum CRP was significantly associated with leptin (beta = 0.326, P = 0.01) and visceral adipose tissue (beta = 0.265, P = 0.035). In conclusion, serum CRP level is significantly associated with obesity, especially the visceral adipose tissue, and serum leptin is another important independent factor associated with CRP in Korean type 2 diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415164     DOI: 10.1007/s00592-009-0125-4

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  8 in total

Review 1.  The Importance of Body Composition in Explaining the Overweight Paradox in Cancer-Counterpoint.

Authors:  Bette J Caan; Elizabeth M Cespedes Feliciano; Candyce H Kroenke
Journal:  Cancer Res       Date:  2018-04-15       Impact factor: 12.701

2.  The serum profile of adipokines in naïve patients with diabetes mellitus type 2 and obesity.

Authors:  D A de Luis; R Aller; O Izaola; H F Ovalle
Journal:  J Clin Lab Anal       Date:  2011-11       Impact factor: 2.352

Review 3.  Role of C-Reactive Protein in Diabetic Inflammation.

Authors:  Julijana Stanimirovic; Jelena Radovanovic; Katarina Banjac; Milan Obradovic; Magbubah Essack; Sonja Zafirovic; Zoran Gluvic; Takashi Gojobori; Esma R Isenovic
Journal:  Mediators Inflamm       Date:  2022-05-17       Impact factor: 4.529

4.  Serum Gamma-glutamyltransferase and Obesity: is there a Link?

Authors:  Viko Coku; Xike Shkembi
Journal:  Med Arch       Date:  2018-04

5.  C-Reactive Protein (CRP) and Leptin Receptor in Obesity: Binding of Monomeric CRP to Leptin Receptor.

Authors:  Manu Sudhakar; Santhi Silambanan; Abhinand S Chandran; Athira A Prabhakaran; Ramya Ramakrishnan
Journal:  Front Immunol       Date:  2018-05-29       Impact factor: 7.561

6.  Increased concentration of C-reactive protein in obese patients with type 2 diabetes is associated with obesity and presence of diabetes but not with macrovascular and microvascular complications or glycemic control.

Authors:  Aneta Fronczyk; Piotr Molęda; Krzysztof Safranow; Wiesław Piechota; Lilianna Majkowska
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

Review 7.  Role of C reactive protein (CRP) in leptin resistance.

Authors:  Marta Letizia Hribal; Teresa Vanessa Fiorentino; Giorgio Sesti
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  Influence of body composition and muscle strength on outcomes after multimodal oesophageal cancer treatment.

Authors:  Eliza R C Hagens; Minke L Feenstra; Maarten A van Egmond; Hanneke W M van Laarhoven; Maarten C C M Hulshof; Piers R Boshier; Donald E Low; Mark I van Berge Henegouwen; Suzanne S Gisbertz
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-02-25       Impact factor: 12.910

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.